SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI11/6/2007 3:54:01 PM
   of 3044
 
2:18PM Millennium Pharm announces MLN1202 significantly reduced marker of systemic inflammation and identifies genomic biomarker for responders (MLNM) 13.45 +0.42 : Co announces MLN1202, a novel, humanized monoclonal antibody met its primary endpoint of reducing C-reactive protein levels in a placebo-controlled, Phase II trial of patients at high-risk for atherosclerotic cardiovascular disease. C.R.P level is an important, independent marker of cardiovascular morbidity and mortality. Additionally, the co announced the identification of a genomic biomarker, which may be used for selecting patients most likely to respond to MLN1202. In this study, the genomic biomarker was identified in 53% of the overall patient population. These data were selected for oral presentation at the American Heart Association Scientific Session being held November 4-7, 2007 in Orlando, Florida.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News